Wissam Harmouch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wissam Harmouch has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Hani Jneid
Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas
3 shared publicationsRavi Thakker
Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA
3 shared publicationsUmamahesh Rangasetty
Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas
3 shared publicationsWissam Khalife
Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA
3 shared publicationsAfaq Motiwala
Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas
2 shared publicationsArun Narayanan
2 shared publications
Latest Publications
- Open Access
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e039601
Invasive Versus Conservative Management Among Older Adult Patients With Non–ST‐Segment–Elevation Myocardial Infarction: A Meta‐Analysis of Randomized Controlled Trials
Background: Older adult patients have been underrepresented in the pivotal trials comparing an invasive versus conservative management for non–ST‐segment–elevation myocardial infarction (NSTEMI). Methods: We performed an electronic search of MEDLINE, Embase, and Cochrane databases through September 2024 for randomized controlled trials comparing invasive versus conservative management of NSTEMI in patients aged ≥70 years. Results: The final analysis included 7 randomized controlled trials with 2997 patients. The weighted mean follow‐up time was 47.1 months, and the mean age was 82.6 years. There was no significant difference in all‐cause mortality between an invasive versus a conservative management approach (27.9% versus 26.6%; risk ratio [RR], 1.05 [95% CI, 0.94–1.18]; I 2 =0%). There was a statistically nonsignificant trend for fewer major adverse cardiac events in the invasive group (28.3% versus 33.4%; RR, 0.82 [95% CI, 0.68–1.00]; P =0.05, I 2 =58%). An invasive approach was associated with a lower risk of recurrent myocardial infarction (RR, 0.76 [95% CI, 0.60–0.97]) and ischemia‐driven revascularization (RR, 0.29 [95% CI, 0.21–0.40]) without an increase in major bleeding (RR, 1.31 [95% CI, 0.86–1.97]) compared with a conservative approach. There were no significant differences between both approaches in cardiovascular mortality, acute cerebrovascular events, or length of hospital stay. Conclusions: Among older adult patients with NSTEMI, there was no significant difference in survival between an invasive or a conservative approach. An invasive approach was associated with a lower risk of recurrent myocardial infarction and ischemia‐driven revascularization without an increase in the risk of major bleeding. The findings should help with informed decision‐making among older adult patients with NSTEMI.
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e039601
Open AccessInvasive Versus Conservative Management Among Older Adult Patients With Non–ST‐Segment–Elevation Myocardial Infarction: A Meta‐Analysis of Randomized Controlled Trials
Background: Older adult patients have been underrepresented in the pivotal trials comparing an invasive versus conservative management for non–ST‐segment–elevation myocardial infarction (NSTEMI). Methods: We performed an electronic search of MEDLINE, Embase, and Cochrane databases through September 2024 for randomized controlled trials comparing invasive versus conservative management of NSTEMI in patients aged ≥70 years. Results: The final analysis included 7 randomized controlled trials with 2997 patients. The weighted mean follow‐up time was 47.1 months, and the mean age was 82.6 years. There was no significant difference in all‐cause mortality between an invasive versus a conservative management approach (27.9% versus 26.6%; risk ratio [RR], 1.05 [95% CI, 0.94–1.18]; I 2 =0%). There was a statistically nonsignificant trend for fewer major adverse cardiac events in the invasive group (28.3% versus 33.4%; RR, 0.82 [95% CI, 0.68–1.00]; P =0.05, I 2 =58%). An invasive approach was associated with a lower risk of recurrent myocardial infarction (RR, 0.76 [95% CI, 0.60–0.97]) and ischemia‐driven revascularization (RR, 0.29 [95% CI, 0.21–0.40]) without an increase in major bleeding (RR, 1.31 [95% CI, 0.86–1.97]) compared with a conservative approach. There were no significant differences between both approaches in cardiovascular mortality, acute cerebrovascular events, or length of hospital stay. Conclusions: Among older adult patients with NSTEMI, there was no significant difference in survival between an invasive or a conservative approach. An invasive approach was associated with a lower risk of recurrent myocardial infarction and ischemia‐driven revascularization without an increase in the risk of major bleeding. The findings should help with informed decision‐making among older adult patients with NSTEMI.
- Open Access
- 1 July 2025
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 16 (7) , 6346-6353
Electrogram Dynamics at the Site of Ventricular Tachycardia Termination During Radiofrequency Ablation
Ventricular tachycardia (VT) is a life-threatening arrhythmia associated with high morbidity and mortality, particularly in patients with structural heart disease. Radiofrequency ablation is an effective procedure to treat patients with this malignant arrhythmia. We report three cases of successful termination of VT using unique catheter ablation techniques. Through these cases and techniques, we highlight the advantages of specific localization of abnormal circuits within the cardiac layer involved, as well as electrogram evidence of tachycardia termination.
- 1 July 2025
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 16 (7) , 6346-6353
Open AccessElectrogram Dynamics at the Site of Ventricular Tachycardia Termination During Radiofrequency Ablation
Ventricular tachycardia (VT) is a life-threatening arrhythmia associated with high morbidity and mortality, particularly in patients with structural heart disease. Radiofrequency ablation is an effective procedure to treat patients with this malignant arrhythmia. We report three cases of successful termination of VT using unique catheter ablation techniques. Through these cases and techniques, we highlight the advantages of specific localization of abnormal circuits within the cardiac layer involved, as well as electrogram evidence of tachycardia termination.
- Open Access
- 1 May 2025
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 16 (5) , 6268-6270
An Antiquated Concept in the Novel Era of Ablation: Zero-fluoroscopy Pulsed Field Ablation for Treatment of Atrial Fibrillation
An Antiquated Concept in the Novel Era of Ablation: Zero-fluoroscopy Pulsed Field Ablation for Treatment of Atrial Fibrillation
- 1 May 2025
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 16 (5) , 6268-6270
Open AccessAn Antiquated Concept in the Novel Era of Ablation: Zero-fluoroscopy Pulsed Field Ablation for Treatment of Atrial Fibrillation
An Antiquated Concept in the Novel Era of Ablation: Zero-fluoroscopy Pulsed Field Ablation for Treatment of Atrial Fibrillation
- 29 April 2025
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 370 (2) , 162-170
Challenges in coronary angiography through radial artery access due to anatomic variations: A single-center experience
- 29 April 2025
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 370 (2) , 162-170
Challenges in coronary angiography through radial artery access due to anatomic variations: A single-center experience
- 19 September 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 75, 64-70
Abbreviated ticagrelor based dual antiplatelet therapy in acute coronary syndrome: A systematic review and meta-analysis
- 19 September 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 75, 64-70
Abbreviated ticagrelor based dual antiplatelet therapy in acute coronary syndrome: A systematic review and meta-analysis
- Open Access
- 2 July 2024
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 25, e944582-e944582-6
Effective Radiation Therapy for Isolated Apical Pulmonary Amyloidoma: A Case Report and Treatment Insight
Objective: Rare disease Background: Amyloidosis refers to an assortment of diseases characterized by the accumulation and deposition of misfolded proteins in the extracellular matrix of tissues and organs. It may present systemically, affecting multiple organs, or locally by affecting a single organ. When the lungs or mediastinal structures are involved, the term pulmonary amyloid is used. Sole pulmonary involvement with amyloid is extremely rare. There is no definitive treatment for this disease, but proposed treatment options include surgery, cytotoxic medications, and external beam radiation therapy (EBRT). Case Report: A 68-year-old man with a left apical lung mass presented with subacute shortness of breath. Comprehensive evaluation of the patient's symptoms and findings, including infectious and oncologic evaluation, were performed. Infectious evaluation revealed positive acid-fast bacilli sputum cultures with Mycobacterium chimerea intracellulare. Biopsy of the mass revealed a Lambda restricted amyloidoma, which is usually seen in lymphoproliferative diseases and disorders. Bone marrow biopsy did not reveal any monoclonal cell lines or neoplasms. Abdominal fat pad biopsy was performed to rule out systemic amyloid and the results were negative. The diagnosis of isolated apical pulmonary amyloidoma was made. EBRT was performed over 12 fractions in 24 mGy, with improvement in the patient's symptoms. Conclusions: The diagnosis of pulmonary amyloid necessitates comprehensive evaluation. There is no specific treatment for pulmonary amyloid; however, there has been success with surgical intervention, cytotoxic medications, and EBRT. Successful treatment of the amyloidoma is based on its anatomic location. We suggest EBRT in fractionated doses for optimal treatment of rare isolated apical pulmonary amyloidoma.
- 2 July 2024
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 25, e944582-e944582-6
Open AccessEffective Radiation Therapy for Isolated Apical Pulmonary Amyloidoma: A Case Report and Treatment Insight
Objective: Rare disease Background: Amyloidosis refers to an assortment of diseases characterized by the accumulation and deposition of misfolded proteins in the extracellular matrix of tissues and organs. It may present systemically, affecting multiple organs, or locally by affecting a single organ. When the lungs or mediastinal structures are involved, the term pulmonary amyloid is used. Sole pulmonary involvement with amyloid is extremely rare. There is no definitive treatment for this disease, but proposed treatment options include surgery, cytotoxic medications, and external beam radiation therapy (EBRT). Case Report: A 68-year-old man with a left apical lung mass presented with subacute shortness of breath. Comprehensive evaluation of the patient's symptoms and findings, including infectious and oncologic evaluation, were performed. Infectious evaluation revealed positive acid-fast bacilli sputum cultures with Mycobacterium chimerea intracellulare. Biopsy of the mass revealed a Lambda restricted amyloidoma, which is usually seen in lymphoproliferative diseases and disorders. Bone marrow biopsy did not reveal any monoclonal cell lines or neoplasms. Abdominal fat pad biopsy was performed to rule out systemic amyloid and the results were negative. The diagnosis of isolated apical pulmonary amyloidoma was made. EBRT was performed over 12 fractions in 24 mGy, with improvement in the patient's symptoms. Conclusions: The diagnosis of pulmonary amyloid necessitates comprehensive evaluation. There is no specific treatment for pulmonary amyloid; however, there has been success with surgical intervention, cytotoxic medications, and EBRT. Successful treatment of the amyloidoma is based on its anatomic location. We suggest EBRT in fractionated doses for optimal treatment of rare isolated apical pulmonary amyloidoma.
- 11 June 2024
- Published by Elsevier in Cardiovascular Pathology
- Vol. 72, 107666
A challenging case of eosinophilic myocarditis leading to heart failure and transplantation
- 11 June 2024
- Published by Elsevier in Cardiovascular Pathology
- Vol. 72, 107666
A challenging case of eosinophilic myocarditis leading to heart failure and transplantation
- Open Access
COMPARING EFFICACY AND SAFETY OF LEFT ATRIAL APPENDAGE CLOSURE DEVICES: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Introduction: Atrial fibrillation-related stroke is a leading cause of morbidity and mortality. Options for prevention include left atrial appendage closure devices or oral anticoagulation. However, it remains unclear which option may be superior overall. Methods: We conducted a systematic review and network meta-analysis of all clinical trials comparing the WATCHMAN, Amplatzer Amulet (Amulet), and/or OACs. The primary outcomes of interest were any stroke and all-cause death. Safety outcomes included any thromboembolism, device embolization, and pericardial effusion. We calculated risk ratios and heterogeneity statistics for each comparison, and calculated the probability of intervention superiority where at least one comparison was significant. Results: There were 441 articles identified from the search, from which 5 eligible RCTs were identified (n=1,811). Compared to OACs (all warfarin), risk of stroke was non-significantly decreased with WATCHMAN (RR=0.90, 95% CI: 0.48, 1.72, I 2 =13.4%), but risk with Amulet was non-significantly lower than WATCHMAN (RR=0.95, 95% CI: 0.50, 1.81). However, observed risk of all-cause death was significantly lower with Amulet than OAC (RR=0.53, 95% CI: 0.33, 0.85, I 2 =0%) and trended towards significance versus WATCHMAN (RR=0.74, 95% CI: 0.55, 1.02, p=0.06). The P-score was 0.982, signifying a >98% probability Amulet was superior to all alternatives. Risk of thromboembolism was non-significantly increased with WATCHMAN (RR=2.04, 95% CI: 0.23, 18.4) and Amulet (RR=1.54, 95% CI: 0.11, 22.1), with head-to-head comparison favoring Amulet (RR=0.76, 95% CI: 0.17, 3.38, I 2 =0%). Versus WATCHMAN, device embolization risk was non-significantly elevated with Amulet (RR= 2.38, 95% CI: 0.67, 8.43, I 2 =0%). Finally, risk of pericardial effusion was significantly elevated with Amulet versus OACs (RR=27.0, 95% CI: 3.48, 210) and versus WATCHMAN (RR=2.11, 95% CI: 1.41, 3.17, I 2 =0%). The inverse P-score for Amulet (0.9995) indicated a very high probability Amulet was inferior to alternatives. Conclusion: While risk of some adverse events was greater with Amulet, we estimated >98% probability Amulet is superior to alternatives in risk of death. Pooled patient-level analyses are warranted.
Open AccessCOMPARING EFFICACY AND SAFETY OF LEFT ATRIAL APPENDAGE CLOSURE DEVICES: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Introduction: Atrial fibrillation-related stroke is a leading cause of morbidity and mortality. Options for prevention include left atrial appendage closure devices or oral anticoagulation. However, it remains unclear which option may be superior overall. Methods: We conducted a systematic review and network meta-analysis of all clinical trials comparing the WATCHMAN, Amplatzer Amulet (Amulet), and/or OACs. The primary outcomes of interest were any stroke and all-cause death. Safety outcomes included any thromboembolism, device embolization, and pericardial effusion. We calculated risk ratios and heterogeneity statistics for each comparison, and calculated the probability of intervention superiority where at least one comparison was significant. Results: There were 441 articles identified from the search, from which 5 eligible RCTs were identified (n=1,811). Compared to OACs (all warfarin), risk of stroke was non-significantly decreased with WATCHMAN (RR=0.90, 95% CI: 0.48, 1.72, I 2 =13.4%), but risk with Amulet was non-significantly lower than WATCHMAN (RR=0.95, 95% CI: 0.50, 1.81). However, observed risk of all-cause death was significantly lower with Amulet than OAC (RR=0.53, 95% CI: 0.33, 0.85, I 2 =0%) and trended towards significance versus WATCHMAN (RR=0.74, 95% CI: 0.55, 1.02, p=0.06). The P-score was 0.982, signifying a >98% probability Amulet was superior to all alternatives. Risk of thromboembolism was non-significantly increased with WATCHMAN (RR=2.04, 95% CI: 0.23, 18.4) and Amulet (RR=1.54, 95% CI: 0.11, 22.1), with head-to-head comparison favoring Amulet (RR=0.76, 95% CI: 0.17, 3.38, I 2 =0%). Versus WATCHMAN, device embolization risk was non-significantly elevated with Amulet (RR= 2.38, 95% CI: 0.67, 8.43, I 2 =0%). Finally, risk of pericardial effusion was significantly elevated with Amulet versus OACs (RR=27.0, 95% CI: 3.48, 210) and versus WATCHMAN (RR=2.11, 95% CI: 1.41, 3.17, I 2 =0%). The inverse P-score for Amulet (0.9995) indicated a very high probability Amulet was inferior to alternatives. Conclusion: While risk of some adverse events was greater with Amulet, we estimated >98% probability Amulet is superior to alternatives in risk of death. Pooled patient-level analyses are warranted.